Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.